Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
Company
Pharmaceutical intelligence for Immunocore with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.